Increased Reticulation without Honeycombing in HRCT linked to Disease Progression in ILD patients Dr.Niharika Harsha B1 Sept 2022 12:15 PM ISTHigher Reticulation on HRCT is associated with increased risk of disease progression within 24 months in Interstitial Lung Disease patients as per a...
Quantitative CT predicts outcomes in patients with idiopathic pulmonary fibrosis: Study Jacinthlyn Sylvia5 Aug 2022 7:45 PM ISTAustralia: The degree of fibrotic abnormalities on baseline computed tomography (CT) is linked with outcomes independent of pulmonary function in a...
Alembic Pharma bags USFDA nod for idiopathic pulmonary fibrosis drug Pirfenidone Ruchika Sharma24 May 2022 5:14 PM ISTPirfenidone Tablets are indicated for the treatment of idiopathic pulmonary fibrosis (IPF).
Roche loses bid to block Sandoz generic lung-disease drug Ruchika Sharma26 March 2022 9:00 AM ISTAndrews ruled for Sandoz on Tuesday and found Sandoz's label only encouraged non-infringing uses of the drug.
Boehringer Ingelheim gets USFDA Breakthrough Therapy Designation for BI 1015550 MD Bureau28 Feb 2022 11:00 AM ISTGermany: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (USFDA) has granted Breakthrough Therapy Designation to its...
Disease Review: Understanding Incidence of Idiopathic pulmonary fibrosis (IPF) in India, Diagnosis and Treatment Dr. Anil Mehndiratta10 Jan 2022 12:24 PM ISTIdiopathic pulmonary fibrosis (IPF), previously known as "Hamman Rich syndrome", "cryptogenic fibrosing alveolitis", and "cirrhosis of the lung", is a...
What was the optimal dose of pirfenidone in large studies on idiopathic pulmonary fibrosis? Dr. Kamal Kant Kohli9 Dec 2021 12:00 PM ISTIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease that is characterized by the irreversible loss of lung function....
Cipla gets CDSCO panel nod for BE study of idiopathic pulmonary fibrosis drug Pirfenidone Medical Dialogues Team7 Sept 2021 2:59 PM ISTNew Delhi: Pharmaceutical major, Cipla has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization...
Antifibrotic therapy reduces mortality and acute exacerbation in idiopathic pulmonary fibrosis: Chest Dr Satabdi Saha24 July 2021 9:15 AM ISTAntifibrotic treatment appears to reduce the risk of all-cause mortality and acute exacerbation in idiopathic pulmonary fibrosis, according to...
JB Chemicals and Pharmaceuticals launches Nintedanib for treatment in Idiopathic Pulmonary Fibrosis (IPF) Meghna A Singhania26 Jun 2021 11:06 AM ISTMumbai: J.B. Chemicals & Pharmaceuticals Ltd. today announced the launch of 'Nintabid' Capsules containing Nintedanib 100mg and 150mg, an oral...
Usual Care Without Antimicrobials sufficient for Patients with IPF: JAMA MD Bureau29 May 2021 9:00 AM ISTLung dysbiosis, observed as increased bacterial load and/or loss of diversity, has been reported in patients with idiopathic pulmonary fibrosis (IPF)....
Antimicrobial therapy of not much benefit in idiopathic pulmonary fibrosis: JAMA Medha Baranwal17 May 2021 9:30 PM ISTUSA: The addition of co-trimoxazole (trimethoprim-sulfamethoxazole) or doxycycline did not significantly improve time to nonrespiratory...
